Hidradenitis suppurativa (HS) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051119

This document outlines details of PBS-subsidised biological medicines for patients with moderate to severe hidradenitis suppurativa (HS).

For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.

Restrictions	Authority level and section	PA assessment	Processing system	Prescriber type	Prescriber self-serve
Initial PB218 form	Written Electronic S85: adalimumab secukinumab	No	OPA	Must be treated by a: dermatologist	Yes - delayed assessment (if free text used)
Continuing PB219 form	Written Electronic S85: adalimumab secukinumab	No	OPA	Must be treated by a: dermatologist	Yes
Subsequent continuing Biosimilar brand only	Streamlined S85: adalimumab	No	N/A	Must be treated by a: dermatologist	N/A
Change or recommencement after a break (< 5 years), or recommencement after a break (>5 years) PB218 form	Written Electronic S85: adalimumab secukinumab	No	OPA	Must be treated by a: dermatologist	Yes
Balance of Supply	Telephone Electronic S85: adalimumab secukinumab	No	OPA	Must be treated by a: dermatologist	Yes

Delayed assessment due to the free text field of prior antibiotics treatment.

Table 2 lists the details of what to check for the delayed assessment.

Service Officers to assess that free text is:

Example

Outcome

Relevant to the question

Name of the most common antibiotics to treat HS:

Approve

Random text

Reject

Escalate to a Pharmaceutical Adviser (PA) by phone if unsure of the antibiotics used.

Operational Information